NOV-002, the lead compound acts as a chemoprotectant and an immunomodulator, in combination with chemotherapy. NOV-002 is approved and marketed in the Russian Fereration by Pharma BAM under the trade... It has been administered to over 10,000 patients, demonstrating clinical efficacy and excellent safety data.
- Mechanism
- Curator reviewed
NOV-002 stimulates the immune system in different ways and stop tumor cells from growing. Drugs used in chemotherapy, such as doxorubicin, cyclophosphamide, and docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more tumor cells. Giving NOV-002 together with chemotherapy before surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be removed.
- Primary indication
- Investigated for use/treatment in breast cancer, lung cancer, and ovarian cancer.Curator reviewed
- Code names
- NOV-002
Resolves to
What you can answer from here — as of July 03, 2026
Which drugs share a target with NOV-002, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account